Drug Discovery App CS WP
-
Integrated Drug Discovery: Hit To PCC In 16 Months
5/8/2026
Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.
-
Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD)
5/6/2026
Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.
-
Accelerating Small Molecule Protein Degrader Development Using High-Content Imaging
5/6/2026
High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.
-
A Miniaturized, Semi-Automated RNA-seq Workflow
4/20/2026
A streamlined RNA‑seq workflow enables high‑throughput gene expression profiling directly from cell lysates, reducing cost and complexity. See how this approach accelerates lead selection.
-
Master The Art Of Pipetting And Learn How To Perform Serial Dilutions
4/16/2026
Accurate serial dilutions depend on more than calculations. Learn how mixing, tip handling, and workflow consistency influence accuracy, as well as how small adjustments can improve reproducibility.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity
4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Bispecific Antibodies Unleashed
2/4/2026
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Leveraging The Immunological Diversity Of The Pentamice® Platform For Covid-19 Antibody Discovery
2/4/2026
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
The Value Of Engaging A Single CDMO For Comprehensive Biologics Services
2/4/2026
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Spatial Organization Of The CAR Is Critical For CAR T Cell Function
1/27/2026
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.